NASDAQ:CPIX

Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis

Cumberland Pharmaceuticals logo
$6.57 +0.77 (+13.28%)
Closing price 04:00 PM Eastern
Extended Trading
$6.59 +0.02 (+0.30%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX)

Advanced

Key Stats

Today's Range
$5.32
▼
$6.75
50-Day Range
$4.22
▼
$8.49
52-Week Range
$1.88
▼
$9.28
Volume
163,212 shs
Average Volume
240,467 shs
Market Capitalization
$98.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions.

Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation. Cumberland also markets products for other conditions, including Vaprisol for certain hospitalized patients with low blood sodium and Vibativ, an antibacterial medicine.

Cumberland sells its products in the United States and uses distribution partners for select international markets. Founder A.J. Kazimi has served as the company’s chairman and chief executive officer.

AI Generated. May Contain Errors.

Cumberland Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

CPIX MarketRank™: 
1.40347361389 of 5 stars

Cumberland Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat, and ranked 1539th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cumberland Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cumberland Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cumberland Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cumberland Pharmaceuticals is 1.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cumberland Pharmaceuticals is 1.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.66.

  • Price to Book Value per Share Ratio

    Cumberland Pharmaceuticals has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.46% of the float of Cumberland Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cumberland Pharmaceuticals has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cumberland Pharmaceuticals has recently decreased by 10.62%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cumberland Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cumberland Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Cumberland Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cumberland Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for CPIX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.07% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.

  • Read more about Cumberland Pharmaceuticals' insider trading history.
Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CPIX Stock News Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Headlines

CPIX Stock Analysis - Frequently Asked Questions

Cumberland Pharmaceuticals' stock was trading at $3.98 at the start of the year. Since then, CPIX stock has increased by 65.1% and is now trading at $6.57.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) issued its earnings results on Tuesday, August, 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.07. The specialty pharmaceutical company earned $166.46 thousand during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a net margin of 274.38% and a negative trailing twelve-month return on equity of 19.50%.
Read the conference call transcript
.

Cumberland Pharmaceuticals' top institutional shareholders include Diversified Trust Co (4.67%), State Street Corp (0.27%), Empowered Funds LLC (0.16%) and Lantern Wealth Advisors LLC (0.09%).
View institutional ownership trends
.

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), onsemi (ON), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), PayPal (PYPL) and Johnson & Johnson (JNJ).

Company Calendar

Last Earnings
8/04/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CPIX
CIK
1087294
Employees
93
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
$4.49
Trailing P/E Ratio
1.46
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.84 million
Net Margins
274.38%
Pretax Margin
-22.69%
Return on Equity
-19.50%
Return on Assets
-8.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.05
Quick Ratio
0.96

Sales & Book Value

Annual Sales
$44.52 million
Price / Sales
2.21
Cash Flow
$0.46 per share
Price / Cash Flow
14.21
Book Value
$4.81 per share
Price / Book
1.37

Miscellaneous

Outstanding Shares
15,000,000
Free Float
8,680,000
Market Cap
$98.55 million
Optionable
Optionable
Beta
0.16

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:CPIX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners